RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
Mayo Clinic
Summary
The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria Participants must meet all the following criteria to be eligible for the study: 1. Adult females and males, aged 18-65 years 2. Must have the capacity to understand study procedures, to comply with them for the entire length of the study, and to provide informed consent. 3. Current major depressive episodes associated with MDD, BD-I, or BD-II, confirmed using the SCID-IV-CV. If a participant has already completed a structured diagnostic interview within the last 2 years or participated in any of the following studies and provided consent to use their information in future…
Interventions
- DrugVortioxetine
Vortioxetine, once daily, for 8 weeks
- DrugCariprazine (Augmentation Phase)
Participants who do not meet remission criteria will enter a second 8-week augmentation phase (Weeks 9-16). During this phase, cariprazine will be added to the existing regimen, administered orally once daily in the morning, starting at 1.5 mg/day and titrated up to 3.0 mg/day in one week.
Location
- Mayo Clinic in RochesterRochester, Minnesota